###### Key messages

-   Among a nationally representative US sample of HIV-infected adults receiving medical care, the prevalence of diagnosed diabetes mellitus (DM) was 10.3%.

-   HIV-infected adults may be likely to have DM at younger ages and in the absence of obesity compared with the general US adult population.

-   The prevalence of DM among HIV-infected adults is high and HIV-care providers should follow existing screening guidelines, which recommend FBG and HbA1c be obtained prior to and after starting antiretroviral therapy.

Introduction {#s1}
============

Diabetes mellitus (DM) is an important cause of morbidity and mortality in the USA. In 2014, there were an estimated 29.1 million persons with DM, of whom 27.8% were undiagnosed.[@R1] Uncontrolled DM can result in significant disability due to complications such as blindness and end-stage renal disease, and is associated with premature mortality due to cancer and vascular disease.[@R2] [@R3] Furthermore, the medical and societal costs of DM are substantial. In 2012, in the USA alone, DM accounted for \$176 billion US in direct medical costs and \$69 billion US in reduced productivity.[@R4]

In the USA, advances in treatment of HIV infection have led to decreased mortality and increased life expectancy among HIV-infected persons.[@R5] [@R6] Consequently, chronic metabolic and cardiovascular diseases such as DM are gaining importance as causes of morbidity and mortality among HIV-infected persons.[@R7] While the burden of DM among the general US adult population has been well described, nationally representative estimates of DM prevalence among HIV-infected adults are lacking. In addition, whether HIV-infected adults are at increased risk of developing DM compared with the general adult population remains controversial.[@R8]

We analyzed nationally representative data from the Medical Monitoring Project (MMP) with the following objectives: (1) estimate DM prevalence among a nationally representative sample of HIV-infected adults; (2) compare the prevalence of DM in HIV-infected adults versus the general US adult population; and (3) identify factors associated with prevalent DM among HIV-infected adults.

Methods {#s2}
=======

Data sources and study design {#s2a}
-----------------------------

We used 2009--2010 data from MMP and the National Health and Nutrition Examination Survey (NHANES) to estimate DM prevalence among HIV-infected adults and the general US adult population, respectively. Our analyses were restricted to adults aged ≥20 years, and excluded pregnant women.

MMP is a surveillance system that produces nationally representative estimates of behavioral and clinical characteristics of HIV-infected adults who receive HIV medical care in the USA. MMP is a cross-sectional survey with a multistage probability design. Detailed descriptions of the sampling methodology and data collection procedures have been published elsewhere.[@R12] Briefly, sampling was conducted in three consecutive stages: (1) USA and dependent areas, (2) outpatient HIV care facilities, and (3) HIV-infected adults aged ≥18 years who made at least one medical care visit to a sampled facility between January and April of 2009 and 2010. Data were collected during June 2009 through May 2011. Facility response rates were 76% (461/603) in 2009 and 81% (474/582) in 2010. Approximately 50% of persons sampled from these facilities completed an interview and had their medical records abstracted. After excluding 81 individuals who were either \<20 years of age or pregnant, our MMP sample included 8610 participants, representing an estimated average of 427 928 HIV-infected adults. The Centers for Disease Control and Prevention (CDC) National Center for HIV, Viral Hepatitis, STD, and TB Prevention has determined MMP to be a non-research public health surveillance activity, and thus, it was not reviewed by a federal institutional review board (IRB). Participating states or territories and facilities obtained local IRB approval to conduct MMP if required locally. Informed consent was obtained from all interviewed participants.

NHANES is a cross-sectional health examination survey with a stratified multistage probability design representative of the general non-institutionalized US population. Descriptions of the sampling plan, and examination and interview protocol are published elsewhere.[@R13] In the 2009--2010 cycle of NHANES, the unweighted response rate for the interviewed and examined persons was 77.3%, resulting in a final sample of 10 253 persons. After excluding individuals \<20 years and pregnant women, 5604 (54.6%) adults remained in the sample, representing an estimated 2.1 million non-institutionalized adults living in the USA in 2009--2010. NHANES was approved by CDC\'s National Center for Health Statistics Institutional Research Ethics Review Board.

Survey sample weights in NHANES and MMP account for the differential probabilities of selection, non-response to survey instruments, and differences between the final sample and the total population.

Measures {#s2b}
--------

The primary outcome variable was DM. In MMP, DM was defined using the following criteria documented in the medical record: (1) physician-diagnosed DM listed on a problem list or in the assessment/plan portion of a progress note; or (2) prescription of insulin or oral hypoglycemic medications (excluding metformin monotherapy). In NHANES, DM was defined using the following criteria: (1) answered 'Yes' to the question: 'Other than during pregnancy, have you ever been told by a doctor or health professional that you have diabetes or sugar diabetes?'; or (2) answered 'Yes' to any of the following questions: (a) 'Are you now taking insulin?'; or (b) 'Are you now taking diabetic pills to lower your blood sugar? These are sometimes called oral agents and oral hypoglycemic agents'. Prescription medication data available in NHANES were used to exclude individuals treated with metformin monotherapy who had responded 'Yes' to question 2b. Exclusion of patients on metformin monotherapy who were not classified as having DM in MMP or answered 'No' to question 1 in NHANES were excluded due to the use of this medication for pre-diabetes and polycystic ovarian syndrome. Laboratory criteria to establish the diagnosis of DM were available for MMP and NHANES; however, they were not used because the fasting nature of blood glucose measurements from laboratory data abstracted from medical charts was unknown, and HbA1c measurements have not been validated for the diagnosis of DM among HIV-infected individuals.[@R10] [@R14] [@R15] Our analyses of DM prevalence were therefore restricted to comparisons of diagnosed DM, as described above.

Sociodemographic variables collected for MMP and NHANES included age, sex at birth, race/ethnicity, education, and poverty level. The number and percentage of participants meeting current poverty guidelines for MMP and NHANES were determined using the US Department of Health and Human Services poverty guidelines. In MMP, body mass index (BMI) measurements were abstracted from medical records for the year prior to the interview. If height was missing (n=1534 (17.7%) in MMP), BMI category was inferred from recorded weight using previously published methods.[@R16] In NHANES, BMI was measured using standardized techniques and equipment. BMI ≥30 kg/m^2^ was considered indicative of obesity. Clinical MMP variables included time since HIV diagnosis, geometric mean CD4+ T-lymphocyte (CD4) count, documented prescription of antiretroviral therapy (ART), and disease stage per CDC criteria.[@R17]

CD4 were described using geometric means, calculated by back transforming the logarithm of CD4; geometric means instead of arithmetic means were used because of the skewed distribution of CD4. MMP participants were classified as being infected with hepatitis C virus (HCV) if any of the following were documented in their medical record: (1) a positive anti-HCV enzyme immunoassay (EIA) or strip immunoblot assay (RIBA); (2) an HCV genotype or (3) HCV-RNA identified through reverse transcriptase--PCR (RT--PCR).[@R18] Indeterminate results of EIA/RIBA, HCV genotype, or HCV-RNA were considered negative. All NHANES participants received a screening HCV antibody test by EIA with confirmation of positive test results using RIBA. Samples with an indeterminate RIBA were tested for HCV-RNA to confirm HCV infection status.

Data analyses {#s2c}
-------------

### Prevalence of and factors associated with DM among HIV-infected adults {#s2c1}

Among HIV-infected adults, we calculated the weighted prevalence and 95% CIs of DM overall and by each of the following characteristics: age (20--44, 45--60, and ≥60 years), sex at birth, race/ethnicity (non-Hispanic White and Black, Hispanic, and Other), education (less than high school, high school or equivalent, and more than high school), poverty level (living at or below the poverty line and living above the poverty line, obesity, time since HIV diagnosis (\<5, 5--9, and ≥10 years), geometric mean CD4 count (0--199, 200--349, 350--499, and ≥500 cells/mm^3^), use of ART during the surveillance period, CDC HIV disease stage (AIDS or nadir CD4 0--199, no AIDS and nadir CD4 200--500, and no AIDS and nadir CD4\>500), and HCV coinfection. All characteristics were analyzed as categorical variables.

To identify factors associated with DM in HIV-infected persons, we used multivariable logistic regression models with DM as the dependent variable, and all previously mentioned characteristics as independent variables. We computed model-adjusted prevalences for all levels of each of the selected characteristics with predicted marginal means, and estimated crude and adjusted prevalence ratios (PR) for each characteristic.[@R19] [@R20] We calculated CIs for adjusted-prevalence estimates and PRs.

### Comparisons between HIV-infected adults receiving medical care and general US population adults {#s2c2}

Weighted percentages and CIs were determined for DM among HIV-infected adults and the general US adult population stratified by age group, sex at birth, race/ethnicity, education, poverty level, obesity, and HCV infection.

We used marginal standardization methods with predicted marginal probabilities to compare the prevalence of DM between MMP and NHANES. In marginal standardization, the predicted probability of the outcome of interest is adjusted to a weighted average reflecting the distribution of covariates in the target population; the marginal effect obtained is the proportion of subjects with the outcome that would have been observed were the study population forced to the exposure level (ie, HIV infection). In other words, given the demographic and clinical characteristics of the populations in MMP and NHANES, what would the predicted probability of DM be were they to be infected with HIV and vice-versa.[@R20]

Under the assumption that MMP and NHANES were two independent samples, with independent design variables and weights, we combined the two data sets and constructed a multivariable logistic model using predicted marginal probabilities with DM as the outcome variable and the following independent variables: an indicator variable for survey type (1=MMP; 0=NHANES), all characteristics listed above, and interaction terms between the indicator variable and all characteristics.[@R21] [@R22]

Using the predicted marginal prevalence of DM, we computed prevalence differences (PD) comparing the two populations, adjusting for all characteristics in MMP and NHANES included in the model.[@R19] Linear contrasts were used to test for heterogeneity among subgroups between the adjusted estimates of diagnosed DM in the HIV-infected and general US adult populations. To assess whether differences in care-seeking could account for differences in DM prevalence between the two populations, we performed a second analysis restricting our comparison of HIV-infected adults receiving medical care to the general US adult population who had received medical care in the previous year.

All analyses were performed using SAS 9.3 (SAS Institute, Cary, North Carolina, USA) and SAS-callable SUDAAN 10.0.1 (RTI International, Research Triangle Park, North Carolina, USA) and accounted for clustering, unequal selection probabilities, and non-response.

Results {#s3}
=======

MMP participants had the following characteristics: male (73.6%), non-Hispanic black (41.3%), aged 45 or more years (59.9%), with greater than a high school education (52.2%), and living above the federal poverty level (56.5%) ([table 1](#BMJDRC2016000304TB1){ref-type="table"}). A quarter of MMP participants had a BMI ≥30 kg/m^2^, 20.6% were HCV-positive, 90.0% had been prescribed ART in the previous year, and 73.0% had their most recent HIV viral load reported \<200 copies/mL. NHANES participants had the following characteristics: male (49.3%), non-Hispanic black (11.7%), aged 45 or more years (51.4%), with greater than a high school education (58.7%), and living above the federal poverty level (91.5%). More than a third (36.0%) of the general US adult population had a BMI ≥30 kg/m^2^, and 1.7% had HCV infection.

###### 

Characteristics of HIV-infected adults and general US population adults, MMP and NHANES 2009--2010

                                                           HIV-infected adults\*   General population adults\*          
  -------------------------------------------------------- ----------------------- ----------------------------- ------ ---------------------
  Total                                                    8610                    --                            5604   --
  Sex at birth                                                                                                          
   Male                                                    6349                    73.6 (70.3 to 76.7)           2745   49.3 (48.1 to 50.6)
   Female                                                  2261                    26.4 (23.3 to 29.7)           2859   50.7 (49.4 to 51.9)
  Race/ethnicity                                                                                                        
   White (non-Hispanic)                                    2869                    34.6 (27.6 to 42.3)           2584   67.3 (59.8 to 74.0)
   Black (non-Hispanic)                                    3512                    41.3 (32.4 to 50.8)           1051   11.7 (10.0 to 13.7)
   Hispanic or Latino                                      1827                    19.3 (14.2 to 25.7)           1656   14.0 (8.8 to 21.3)
   Other                                                   402                     4.9 (3.9 to 6.0)              313    7.1 (5.1 to 9.9)
  Age in years                                                                                                          
   20--44                                                  3412                    40.1 (38.7 to 41.5)           2518   48.6 (46.2 to 51.1)
   45--60                                                  4366                    50.3 (48.9 to 51.6)           1473   29.8 (28.5 to 31.1)
   ≥60                                                     832                     9.6 (8.8 to 10.6)             1613   21.6 (20.1 to 23.2)
  Education                                                                                                             
   Less than high school                                   1937                    21.5 (19.1 to 24.1)           1570   18.4 (16.5 to 20.5)
   High school or equivalent                               2314                    26.3 (24.1 to 28.7)           1289   22.9 (20.7 to 25.2)
   More than high school                                   4356                    52.2 (47.7 to 56.6)           2722   58.7 (55.7 to 61.7)
  Living at or below poverty line†                                                                                      
   Yes                                                     3790                    43.5 (39.6 to 47.5)           713    8.5 (7.0 to 10.3)
   No                                                      4565                    56.5 (52.5 to 60.4)           4608   91.5 (89.7 to 93.0)
  Obese (BMI ≥30 kg/m^2^)                                                                                               
   Yes                                                     2071                    25.5 (23.9 to 27.2)           2073   36.0 (34.0 to 38.2)
   No                                                      6208                    74.5 (72.8 to 76.2)           3291   64.0 (61.9 to 66.0)
  Hepatitis C virus‡                                                                                                    
   Positive                                                1556                    20.6 (18.7 to 22.7)           106    1.7 (1.2 to 2.4)
   Negative                                                5590                    79.4 (77.3 to 81.3)           5190   98.3 (97.6 to 98.8)
  Time since HIV diagnosis                                                                                              
   Less than 5 years                                       1866                    22.4 (20.7 to 24.1)           --     --
   5--9 years                                              1932                    22.6 (21.6 to 23.6)           --     --
   10 or more years                                        4806                    55.0 (52.8 to 57.3)           --     --
  AIDS/nadir CD4 count in cells/mm^3^                                                                                   
   AIDS or nadir CD4 0-199                                 5952                    68.5 (67.2 to 69.7)           --     --
   No AIDS and nadir CD4 200--500                          2098                    24.8 (23.4 to 26.2)           --     --
   No AIDS and nadir CD4 \>500                             540                     6.8 (6.0 to 7.6)              --     --
  Geometric mean CD4 past 12 months                                                                                     
   0--199 cells/mm^3^                                      1118                    13.0 (12.1 to 13.9)           --     --
   200--349 cells/mm^3^                                    1486                    17.9 (16.9 to 19.1)           --     --
   350--499 cells/mm^3^                                    1949                    23.6 (22.6 to 24.7)           --     --
   ≥500 cells/mm^3^                                        3739                    45.5 (44.0 to 47.0)           --     --
  Prescribed ART                                                                                                        
   Yes                                                     7751                    90.0 (89.2 to 90.7)           --     --
   No                                                      828                     10.1 (9.3 to 10.8)            --     --
  Most recent viral load undetectable or \<200 copies/mL                                                                
   Yes                                                     6287                    73.0 (71.0 to 75.0)           --     --
   No                                                      2323                    27.0 (25.1 to 29.1)           --     --

\*Includes adults ≥20 years of age and excludes pregnant women.

†Calculated using the ratio of annual household income to number of people in the household.

‡A total of n=7146 and n=5295 were screened for hepatitis C (HCV) in MMP and NHANES, respectively. HCV positivity was defined as having a documented positive anti-HCV enzyme immunoassay or strip immunoblot assay RIBA, HCV genotype, or HCV RNA through reverse transcriptase--PCR (RT--PCR).

ART, antiretroviral therapy; BMI, body mass index; MMP, Medical Monitoring Project; NHANES, National Health and Nutrition Examination Survey.

The unadjusted prevalence of DM (CI) among HIV-infected adults was 10.3% (9.1% to 11.5%), and was higher compared with the general US adult population (8.3% (7.2% to 9.4%)) as well as the general US adult population having received care in the previous 12 months (9.7% (8.4% to 11.1%)) (data not shown). Among HIV-infected adults with diagnosed DM, 3.9% (95% CI 2.9% to 5.2%) had DM type 1, 52.3% (CI 46.7% to 57.8%) had DM type 2, and 43.9% (CI 38.1% to 49.8%) had unspecified DM. After adjusting for differences in distributions of sex, age, race/ethnicity, education, poverty, obesity, and HCV infection prevalence, the adjusted PD (aPD) of DM in HIV-infected adults versus the general US adult population was 3.8% ([table 2](#BMJDRC2016000304TB2){ref-type="table"}). The largest difference in DM prevalence among HIV-infected adults relative to their counterparts in the general US adult population occurred among those with HCV infection (6.3%), those with a high school or equivalent education (5.1%), women (5.0%), non-Hispanics whites (4.9%), individuals living at or below the poverty line (4.6%), obese individuals (4.4%) and ages 20--44 years (4.1%). After restricting the NHANES population to adults who had received care in the previous 12 months, associations were similar to those described above with a slight decrease in the magnitude of DM PD ([table 3](#BMJDRC2016000304TB3){ref-type="table"}).

###### 

Predicted marginal prevalence and prevalence comparisons of diagnosed diabetes among HIV-infected adults and general US population adults, MMP and NHANES 2009, 2010

                                     HIV-infected adults   General population adults                                              
  ---------------------------------- --------------------- --------------------------- --------------------- -------------------- ----------
  Total                              11.8 (10.1 to 13.7)   8.0 (7.1 to 9.1)            1.47 (1.21 to 1.78)   3.8 (1.8 to 5.8)     0.0002
  Sex at birth                                                                                                                    
   Male                              11.2 (9.9 to 12.7)    8.9 (7.2 to 10.7)           1.28 (1.02 to 1.60)   2.4 (0.3 to 4.6)     0.03
   Female                            12.4 (10.1 to 15.2)   7.4 (6.4 to 8.5)            1.68 (1.31 to 2.15)   5.0 (2.3 to 7.7)     0.0003
  Race/ethnicity                                                                                                                  
   White (non-Hispanic)              11.4 (9.6 to 13.5)    6.5 (5.3 to 7.9)            1.76 (1.37 to 2.28)   4.9 (2.7 to 7.2)     \<0.0001
   Black (non-Hispanic)              13.1 (11.1 to 15.4)   11.8 (9.7 to 14.3)          1.11 (0.87 to 1.42)   1.3 (−1.7 to 4.3)    0.4
   Hispanic or Latino                13.1 (10.3 to 16.4)   11.4 (9.4 to 13.8)          1.14 (0.85 to 1.54)   1.6 (−2.1 to 5.4)    0.4
   Other                             11.7 (8.5 to 15.9)    14.8 (11.4 to 18.9)         0.79 (0.53 to 1.17)   −3.1 (−8.3 to 2.1)   0.2
  Age in years                                                                                                                    
   20--44                            6.4 (5.3 to 7.6)      2.3 (1.7 to 3.2)            2.77 (1.91 to 4.02)   4.1 (2.7 to 5.5)     \<0.0001
   45--60                            13.0 (11.0 to 15.2)   9.1 (7.5 to 10.9)           1.43 (1.12 to 1.81)   3.9 (1.3 to 6.5)     0.004
   ≥60                               21.9 (17.9 to 26.6)   19.5 (16.8 to 22.6)         1.12 (0.88 to 1.44)   2.4 (−2.8 to 7.6)    0.4
  Education                                                                                                                       
   Less than high school             13.0 (10.3 to 16.2)   10.6 (9.3 to 12.1)          1.22 (0.94 to 1.59)   2.3 (−0.9 to 5.6)    0.2
   High school or equivalent         11.4 (9.9 to 13.6)    6.3 (5.3 to 7.5)            1.81 (1.39 to 2.35)   5.1 (2.6 to 7.5)     0.0001
   More than high school             11.6 (9.9 to 13.6)    7.8 (6.5 to 9.4)            1.48 (1.17 to 1.87)   3.8 (1.5 to 6.1)     0.001
  Living at or below poverty line‡                                                                                                
   No                                11.8 (10.1 to 13.8)   8.1 (7.2 to 9.1)            1.46 (1.20 to 1.77)   3.7 (1.6 to 5.8)     0.0005
   Yes                               11.8 (9.8 to 14.1)    7.2 (5.4 to 9.7)            1.63 (1.17 to 2.27)   4.6 (1.7 to 7.4)     0.002
  Obesity (BMI ≥30 kg/m^2^)                                                                                                       
   No                                7.8 (6.2 to 9.9)      4.3 (3.5 to 5.4)            1.81 (1.32 to 2.49)   3.5 (1.4 to 5.6)     0.0009
   Yes                               18.1 (15.8 to 20.7)   13.7 (12.1 to 15.6)         1.32 (1.10 to 1.58)   4.4 (1.5 to 7.4)     0.003
  Hepatitis C virus§                                                                                                              
   Positive                          13.4 (11.0 to 16.2)   7.1 (3.8 to 13.1)           1.88 (0.98 to 3.61)   6.3 (1.1 to 11.4)    0.02
   Negative                          11.8 (10.1 to 13.7)   8.1 (7.1 to 9.1)            1.46 (1.21 to 1.77)   3.7 (1.7 to 5.7)     0.0003

\*Prevalence ratio using NHANES as the referent category.

†Prevalence difference calculated as prevalence(MMP)--prevalence(NHANES).

‡Calculated using the ratio of annual household income to number of people in the household.

§A total of n=7146 and n=5295 were screened for hepatitis C (HCV) in MMP and NHANES, respectively. HCV positivity was defined as having a documented positive anti-HCV enzyme immunoassay or strip immunoblot assay RIBA, HCV genotype, or HCV RNA through reverse transcriptase--PCR (RT--PCR).

aPD, adjusted prevalence difference; aPR, adjusted prevalence ratio; BMI, body mass index; MMP, Medical Monitoring Project; NHANES, National Health and Nutrition Examination Survey.

###### 

Predicted marginal prevalence and prevalence comparisons of diagnosed diabetes among HIV-infected adults and general US population adults having received medical care in the previous 12 months, MMP and NHANES 2009--2010

                                     HIV-infected adults   General population adults                                               
  ---------------------------------- --------------------- --------------------------- --------------------- --------------------- ----------
  Total                              12.4 (10.6 to 14.4)   9.38 (8.2 to 10.7)          1.32 (1.09 to 1.61)   3.0 (0.8 to 5.2)      0.007
  Sex at birth                                                                                                                     
   Male                              11.7 (10.3 to 13.3)   10.6 (8.6 to 13)            1.11 (0.88 to 1.4)    1.1 (−1.4 to 3.7)     0.4
   Female                            13.0 (10.5 to 15.9)   8.36 (7.3 to 9.6)           1.55 (1.22 to 1.97)   4.6 (1.7 to 7.5)      0.002
  Race/ethnicity                                                                                                                   
   White (non-Hispanic)              12.0 (10.1 to 14.2)   7.58 (6.2 to 9.2)           1.58 (1.23 to 2.04)   4.4 (1.9 to 6.9)      0.0005
   Black (non-Hispanic)              13.8 (11.7 to 16.2)   13.47 (11.3 to 15.9)        1.02 (0.81 to 1.29)   0.3 (−2.8 to 3.4)     0.8
   Hispanic or Latino                13.8 (10.9 to 17.3)   14 (11.6 to 16.7)           0.98 (0.73 to 1.31)   −0.3 (−4.3 to 3.8)    0.9
   Other                             12.3 (8.9 to 16.7)    17.22 (13.3 to 22)          0.71 (0.48 to 1.06)   −4.9 (−11.0 to 0.8)   0.09
  Age in years                                                                                                                     
   20--44                            6.5 (5.4 to 7.8)      2.72 (1.9 to 3.9)           2.37 (1.59 to 3.54)   3.7 (2.2 to 5.3)      \<0.0001
   45--60                            13.1 (11.1 to 15.4)   10.35 (8.6 to 12.4)         1.27 (1.00 to 1.61)   2.8 (−0.0 to 5.6)     0.05
   ≥60                               22.2 (18.1 to 26.9)   20.54 (17.8 to 23.6)        1.08 (0.85 to 1.37)   1.6 (−3.6 to 6.9)     0.5
  Education                                                                                                                        
   Less than high school             13.6 (10.8 to 17)     13.12 (11.3 to 15.1)        1.04 (0.79 to 1.36)   0.5 (−3.2 to 4.2)     0.8
   High school or equivalent         11.9 (9.9 to 14.4)    7.32 (6 to 8.9)             1.63 (1.23 to 2.15)   4.6 (1.9 to 7.3)      0.001
   More than high school             12.2 (10.3 to 14.4)   8.94 (7.4 to 10.8)          1.36 (1.07 to 1.74)   3.3 (0.7 to 5.8)      0.01
  Living at or below poverty line‡                                                                                                 
   No                                12.4 (10.6 to 14.5)   9.43 (8.3 to 10.6)          1.31 (1.08 to 1.60)   3.0 (0.7 to 5.2)      0.01
   Yes                               12.4 (10.3 to 14.8)   8.72 (6.6 to 11.5)          1.42 (1.03 to 1.95)   3.6 (0.5 to 6.8)      0.02
  Obesity (BMI ≥30 kg/m^2^)                                                                                                        
   No                                8.1 (6.4 to 10.3)     5.14 (4.1 to 6.5)           1.58 (1.13 to 2.21)   3.0 (0.7 to 5.3)      0.01
   Yes                               18.7 (16.2 to 21.4)   15.35 (13.5 to 17.4)        1.22 (1.01 to 1.46)   3.3 (0.2 to 6.5)      0.04
  Hepatitis C virus§                                                                                                               
   Positive                          14.0 (11.5 to 17)     8.22 (4.4 to 14.8)          1.71 (0.90 to 3.23)   5.8 (0.1 to 11.5)     0.04
   Negative                          12.4 (10.6 to 14.4)   9.4 (8.3 to 10.7)           1.32 (1.08 to 1.60)   3.0 (0.8 to 5.2)      0.009

\*Prevalence ratio using NHANES as the referent category.

†Prevalence difference calculated as prevalence(MMP)--prevalence(NHANES).

‡Calculated using the ratio of annual household income to number of people in the household.

§A total of n=7146 and n=5295 were screened for hepatitis C (HCV) in MMP and NHANES, respectively. HCV positivity was defined as having a documented positive anti-HCV enzyme immunoassay or strip immunoblot assay RIBA, HCV genotype, or HCV RNA through reverse transcriptase--PCR (RT--PCR).

aPD, adjusted prevalence difference; aPR, adjusted prevalence ratio; BMI, body mass index; MMP, Medical Monitoring Project; NHANES, National Health and Nutrition Examination Survey.

Among HIV-infected adults, DM prevalence varied by selected characteristics ([table 4](#BMJDRC2016000304TB4){ref-type="table"}). The adjusted DM prevalence was lowest among those aged 20--44 years (6.7%) and highest among those aged ≥60 years (19.6%), and obese (18.9%) ([table 4](#BMJDRC2016000304TB4){ref-type="table"}). Factors independently associated with total DM among HIV-infected adults included increasing age, obesity, increasing time since HIV diagnosis, and geometric mean CD4.

###### 

Prevalence of and factors associated with diagnosed diabetes mellitus among HIV-infected adults, MMP 2009--2010

                                        Sample n\*   Weighted prevalence % (95% CI)   Adjusted weighted prevalence % (95% CI)   cPR (95% CI)          aPR (95%CI)           p Value†
  ------------------------------------- ------------ -------------------------------- ----------------------------------------- --------------------- --------------------- ----------
  Total                                 8610         10.2 (9.1 to 11.4)               10.7 (9.6 to 11.8)                        --                    --                    --
  Sex at birth                          0.2                                                                                                                                 
   Male                                 6349         9.5 (8.3 to 10.7)                10.3 (9.2 to 11.5)                        Ref                   Ref                   
   Female                               2261         12.4 (10.7 to 14.0)              11.5 (9.7 to 13.6)                        1.30 (1.14 to 1.49)   1.12 (0.94 to 1.33)   
  Race/ethnicity                        0.1                                                                                                                                 
   White (non-Hispanic)                 2869         8.9 (7.4 to 10.5)                9.4 (8.0 to 10.9)                         ref                   ref                   
   Black (non-Hispanic)                 3512         11.3 (9.9 to 12.7)               11.5 (10.0 to 13.2)                       1.26 (1.07 to 1.50)   1.23 (1.02 to 1.48)   
   Hispanic or Latino                   1827         10.4 (8.7 to 12.1)               11.2 (9.3 to 13.6)                        1.17 (0.93 to 1.46)   1.20 (0.96 to 1.50)   
   Other                                402          10.3 (6.7 to 13.9)               10.7 (7.8 to 14.7)                        1.16 (0.87 to 1.53)   1.15 (0.87 to 1.52)   
  Age in years                          \<0.0001                                                                                                                            
   20--44                               3412         5.8 (4.9 to 6.7)                 6.7 (5.8 to 7.7)                          ref                   ref                   
   45--60                               4366         12.0 (10.7 to 13.4)              11.9 (10.5 to 13.6)                       2.07 (1.82 to 2.36)   1.79 (1.53 to 2.08)   
   ≥60                                  832          19.3 (16.1 to 22.6)              19.6 (16.3 to 23.5)                       3.33 (2.83 to 3.91)   2.94 (2.36 to 3.67)   
  Education                             0.6                                                                                                                                 
   Less than high school                1937         12.1 (10.1 to 14.1)              11.5 (9.7 to 13.6)                        1.24 (1.00 to 1.55)   1.09 (0.89 to 1.34)   
   High school or equivalent            2314         9.7 (8.0 to 11.5)                10.3 (8.6 to 12.2)                        1.00 (0.84 to 1.18)   0.97 (0.80 to 1.18)   
   More than high school                4356         9.7 (8.3 to 11.2)                10.5 (9.3 to 12)                          ref                   ref                   
  Living at or below poverty line‡      0.9                                                                                                                                 
    No                                  4565         10.4 (8.8 to 11.3)               10.6 (9.2 to 12.2)                        ref                   ref                   
    Yes                                 3790         10.7 (9.1 to 12.2)               10.8 (9.3 to 12.5)                        1.06 (0.92 to 1.23)   1.02 (0.83 to 1.25)   
  Obesity (BMI ≥30 kg/m^2^)                                                                                                                                                 \<0.0001
   No                                   6208         7.8 (6.4 to 9.1)                 7.9 (6.7 to 9.4)                          ref                   ref                   
   Yes                                  2071         17.7 (16.4 to 19.1)              18.9 (17 to 20.9)                         2.29 (1.88 to 2.79)   2.38 (1.91 to 2.95)   
  Hepatitis C virus§                    0.3                                                                                                                                 
   Positive                             1556         12.9 (10.9 to 14.9)              11.6 (9.8 to 13.6)                        1.31 (1.10 to 1.58)   1.11 (0.92 to 1.35)   
   Negative                             5590         9.8 (8.7 to 11.0)                10.4 (9.2 to 11.8)                        ref                   ref                   
  Time since HIV diagnosis              \<0.0001                                                                                                                            
   Less than 5 years                    1866         5.4 (3.9 to 6.9)                 7.0 (5.3 to 9.1)                          ref                   ref                   
   5--9 years                           1932         8.6 (7.0 to 10.2)                9.8 (8.1 to 11.8)                         1.59 (1.22 to 2.08)   1.41 (1.06 to 1.87)   
   10 or more years                     4806         12.9 (11.6 to 14.2)              12.3 (11.1 to 13.5)                       2.40 (1.88 to 3.05)   1.77 (1.38 to 2.27)   
  AIDS/nadir CD4 count in cells/mm^3^   0.3                                                                                                                                 
   AIDS or nadir CD4 0--199             5952         10.8 (9.7 to 11.8)               10.5 (9.5 to 11.6)                        1.27 (1.08 to 1.52)   1.01 (0.83 to 1.22)   
   No AIDS and nadir CD4 200--500       2098         8.5 (6.5 to 10.4)                10.4 (8.6 to 12.6)                        ref                   ref                   
   No AIDS and nadir CD4 \>500          540          11.2 (8.0 to 14.3)               13.5 (9.6 to 18.6)                        1.32 (0.97 to 1.79)   1.29 (0.94 to 1.78)   
  Geometric mean CD4 past 12 months     0.0007                                                                                                                              
   0--199 cells/mm^3^                   1118         9.8 (7.8 to 11.8)                10.1 (7.9 to 12.7)                        1.11 (0.87 to 1.40)   1.14 (0.88 to 1.47)   
   200--349 cells/mm^3^                 1486         9.8 (7.9 to 11.7)                11.4 (9.5 to 13.7)                        1.11 (0.89 to 1.37)   1.29 (1.05 to 1.59)   
   350--499 cells/mm^3^                 1949         8.9 (7.8 to 10.0)                8.8 (7.7 to 10.1)                         ref                   ref                   
   ≥500 cells/mm^3^                     3739         11.3 (9.8 to 12.8)               11.5 (10.1 to 13.2)                       1.27 (1.13 to 1.90)   1.30 (1.14 to 1.50)   
  Prescribed ART                        0.054                                                                                                                               
   No                                   828          7.2 (5.1 to 9.4)                 8.3 (6.2 to 10.9)                         Ref                   Ref                   
   Yes                                  7751         10.6 (9.5 to 11.7)               10.9 (9.8 to 12.1)                        1.47 (1.13 to 1.90)   1.32 (0.99 to 1.76)   

\*Includes adults aged ≥ 20 years.

†p Value of association for the multivariable model.

‡Calculated using the ratio of annual household income to number of people in the household.

§A total of n=7146 were screened for hepatitis C (HCV) in MMP. HCV positivity was defined as having a documented positive anti-HCV enzyme immunoassay or strip immunoblot assay RIBA, HCV genotype, or HCV RNA through reverse transcriptase--PCR (RT--PCR).

aPR, adjusted prevalence ratio; ART, antiretroviral therapy; BMI, body mass index; cPR, crude prevalence ratio; MMP, Medical Monitoring Project.

Discussion {#s4}
==========

Among a nationally representative US sample of HIV-infected adults receiving medical care in 2009 and 2010, the DM prevalence was 10.3%; increasing age, obesity, longer duration of HIV infection, and geometric mean CD4 were independently associated with a higher DM prevalence. When compared with the general US adult population, HIV-infected individuals had a 3.8% higher prevalence of DM after adjusting for age, sex, race/ethnicity, education, poverty-level, obesity, and HCV infection. This analysis provides the first nationally representative estimate of DM burden among HIV-infected adults and suggests that HIV-infected persons may be more likely to have DM at younger ages and in the absence of obesity compared with the general US adult population.

Our estimates of DM prevalence among HIV-infected adults are lower compared with previous US studies. The Multicenter AIDS Cohort Study reported 14% DM prevalence among 411 men who have sex with men recruited from 1999 to 2003.[@R8] The Veterans Aging Cohort Study Virtual Cohort observed a similar baseline prevalence (14%) in a cohort of 27 350 HIV-infected veterans recruited from 2003 to 2009.[@R23] These differences may reflect the burden of undiagnosed diabetes measured with fasting blood glucose and HbA1c. The HIV Outpatient Study (HOPS) reported a higher DM prevalence among HIV-infected women (19%) compared with HIV-infected men (12%), a finding that although not statistically significant was observed in our sample.[@R24] Conversely, DM prevalence among HIV-infected individuals in non-US cohorts is significantly lower than our estimate, ranging from 2.7% to 3.3%.[@R9] [@R25] [@R26]

Similar to previous studies, we observed a strong association between both increasing age and obesity and prevalent DM among HIV-infected individuals,[@R8] [@R10] [@R11] [@R24] [@R26] [@R27] suggesting that these traditional risk factors play a major role in the development of DM among HIV-infected adults. Despite evidence suggesting a link between ART and DM, ART prescription in the past year was not associated with prevalent DM in our study.[@R9] [@R24] [@R26] This may be due to our inability to assess cumulative exposure to ART in MMP. The ARTs indinavir, zidovudine, saquinavir, stavudine, and didanosine have been associated with a higher prevalence of DM;[@R9] [@R24] [@R25] only a small percentage of HIV-infected adults in MMP were currently prescribed these agents (0.4% indinavir, 11.2% zidovudine, 1.0% saquinavir, 1.2% stavudine, and 2.4% didanosine), which may also account for the null association between ART exposure and DM. Time since HIV diagnosis was significantly associated with a higher DM prevalence. Although the exact mechanistic pathways measured by this variable are hard to elucidate, it may serve as a proxy for older age, exposure to chronic inflammation due to HIV infection, as well as cumulative exposure to ART, all of which have been linked to insulin resistance.[@R24] [@R26] Another surrogate marker for systemic inflammation, CD4 count nadir, was not associated with increased prevalence of DM after adjusting for other covariates. This is contrary to previous studies which have linked CD4+ nadir \<200 cells/μL with increased levels of interleukin 6, high-sensitivity C reactive protein, and soluble tumor necrosis receptors.[@R26] [@R31] [@R32] In addition, geometric mean CD4 count was associated with a higher prevalence of DM in our sample; however, the lack of clear directionality makes it hard to interpret. Taken together, our results highlight the need for more nuanced measures of chronic inflammation present in HIV infection and their interaction with traditional risk factors such as obesity.

The aPD of DM between HIV-infected adults and the general US adult population was heterogeneous by subpopulation. HIV-infected women had a 5% higher prevalence than their counterparts in the general population, an effect that was independent of obesity. There is evidence that the use of ART may increase conversion to DM among women with high-risk genetic polymorphisms;[@R33] however, sex-specific differences in insulin resistance, particularly the role of sex hormones in the setting of HIV infection, remain understudied. Beyond the effect of ART on insulin resistance and development of DM, chronic inflammation during HIV infection may accelerate the development of comorbid conditions such as DM.[@R32] Although this chronic inflammatory state may explain the development of DM among HIV-infected adults at younger ages and among the non-obese, there is a continued need for research assessing other important risk factors for DM among HIV-infected individuals, including diet and exercise, as well as a deeper understanding of insulin and glucose homeostasis in the setting of HIV infection.

Finally, although HCV has been described as a risk factor for DM in the general population, our findings indicate that HIV may compound the deleterious effects of HCV, putting HIV/HCV coinfected individuals at even higher risk of DM.[@R34] Observed differences could be due to a lower engagement in medical care by HCV-infected adults in the general population and suboptimal screening practices.[@R35] Nevertheless, this finding is particularly relevant, given the availability of directly acting antiviral agents as curative HCV therapy and highlights a potential additional benefit of HCV treatment for coinfected patients.[@R36]

Based on our findings, as well as current literature regarding DM among HIV-infected individuals, there are several important implications. First, HIV-care providers should follow existing DM screening guidelines, which recommend FBG and HbA1c be obtained prior to and after starting ART.[@R37] Second, existing data from prospective studies should be examined to determine if screening guidelines should be modified, given the increased prevalence of DM among younger and non-obese HIV-infected persons. Third, improved tests for DM diagnosis and monitoring among HIV-infected persons should be explored, given studies that have demonstrated the diagnostic limitations of HbA1c in this population.[@R10] [@R14] [@R15] Finally, additional research will be important to identify optimal DM management strategies among HIV-infected persons as traditional strategies to improve insulin sensitivity such as weight loss and diabetic medical therapy have been shown to be less effective among HIV-infected individuals.[@R38] [@R39]

This analysis is subject to several limitations. First, the definition of diagnosed DM was different between MMP (medical record abstraction) and NHANES (self-reported) and may be a source of bias. A recent cohort-based validation of prevalence of DM based on self-report showed a specificity and negative predictive value \>95%, with a sensitivity and positive predictive value between 60% and 70%.[@R40] This indicates that were there a bias introduced by self-reporting of DM, it would be towards and increased prevalence of DM with self-report. Furthermore, comparisons between self-reported and medical record-based estimates of DM have shown substantial agreement between both measures, and in some cases, an underestimation of DM prevalence in medical records relative to self-report.[@R41] Second, there is a risk of observer bias in our sample, given differences in engagement in care between our samples. We addressed this by performing a sensitivity analysis restricting the NHANES sample to adults having received care in the previous 12 months. Although we observed only slight changes in the magnitude of the associations, there is a possibility of overestimation of the PD between MMP and NHANES. Third, risk factors for DM, such as family history/genetics, diet, and exercise, were not included in this analysis and could explain some of the excess prevalence observed among HIV-infected adults. However, the inclusion of patients with type 1 diabetes is unlikely to have resulted in the excess diabetes prevalence observed in our study as the prevalence of type 1 diabetes in NHANES has been estimated to range between 3.6% and 4.8%.[@R44] Fourth, the measurement of BMI and HCV were standardized for the NHANES population and not for MMP participants resulting in a biased association between these variables and DM when comparing NHANES and MMP participants. Fifth, MMP data are representative of HIV-infected persons receiving medical care and do not necessarily reflect DM prevalence among HIV-infected persons not diagnosed or not receiving care. Sixth, the increased prevalence of DM among HIV-infected women relative to the general US adult population may be due to misclassification bias; although we excluded pregnant women and diagnoses labeled gestational diabetes in the medical record of MMP participants, female patients with gestational diabetes may have been mislabeled and included in our sample. Finally, the NHANES population included HIV-infected adults who may or may not have received medical care. However, the prevalence of HIV-infected individuals in the NHANES population is negligible (0.21%).[@R45] Although diabetes rates were standardized to the combined population of MMP and NHANES, given the very small percentage represented by MMP in the general US adult population, the bias introduced should be minimal.

Conclusion {#s5}
==========

We presented the first nationally representative estimate of DM prevalence among HIV-infected adults receiving medical care in the USA in 2009--2010 where 1 in 10 HIV-infected adults had a diagnosis of DM. Although obesity is a risk factor for prevalent DM among HIV-infected adults, when compared with the general US adult population, HIV-infected adults may have higher DM prevalence at younger ages and in the absence of obesity. Healthcare providers caring for HIV-infected patients should follow existing DM screening guidelines. Given the large burden of DM among HIV-infected adults, additional research would help to determine whether DM screening guidelines should be modified to include HIV infection as a risk factor for DM and to identify optimal management strategies in this population.
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